1,700 Shares in IQVIA Holdings Inc. (NYSE:IQV) Acquired by Compound Global Advisors LLC

Compound Global Advisors LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,700 shares of the medical research company’s stock, valued at approximately $334,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in IQVIA in the 3rd quarter worth about $147,683,000. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB raised its holdings in shares of IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after buying an additional 452,029 shares during the last quarter. Finally, KBC Group NV boosted its position in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after buying an additional 250,458 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IQV has been the topic of several recent analyst reports. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Finally, Stephens started coverage on shares of IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $252.50.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.60% of the stock is currently owned by insiders.

IQVIA Trading Down 0.7 %

NYSE:IQV opened at $206.67 on Tuesday. The stock has a fifty day simple moving average of $200.67 and a 200 day simple moving average of $219.27. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $37.51 billion, a price-to-earnings ratio of 27.56, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.